MAM
ARRY

Martingale Asset Management’s Array Biopharma Inc ARRY Stock Holding History

Martingale Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-13,327
Closed -$218K – 1037
2018
Q1 		$218K Buy
+13,327
New +$213K ﹤0.01% 908

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Martingale Asset Management's ARRY Position: Q2 2018 in Review

Martingale Asset Management sold out of Array Biopharma Inc (ARRY) in Q2 2018, closing a stake of 13,327 shares — an estimated $218K sold.

Martingale Asset Management first reported a position in ARRY in Q1 2018 and held it in 1 quarter. The position peaked at $218K in Q1 2018. 223 funds tracked by Wall St. Rank hold ARRY as of Q2 2018.

  • Martingale Asset Management reported no remaining Array Biopharma Inc position as of Q2 2018 after selling out during the quarter.
  • Martingale Asset Management sold 13,327 Array Biopharma Inc shares in Q2 2018, an estimated $218K.
  • Martingale Asset Management first reported a position in Array Biopharma Inc in Q1 2018 and held it in 1 quarter.
  • Martingale Asset Management's Array Biopharma Inc position peaked at $218K in Q1 2018.
  • 223 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2018.

Based on Martingale Asset Management's 13F filing for Q2 2018, filed 9 Aug 2018.